MétaCan
Menu
Back to cohort
Record W4200614895 · doi:10.1136/bmjno-2021-000218

Vagus nerve stimulation therapy in people with drug-resistant epilepsy (CORE-VNS): rationale and design of a real-world post-market comprehensive outcomes registry

2021· article· en· W4200614895 on OpenAlexfundno aff
Arjune Sen, Ryan Verner, James Valeriano, S. W. Ricky Lee, Muhammad Zafar, Rhys H. Thomas, Katarzyna Kotulska, Ellen Jespers, Maxine Dibué, Patrick Kwan

Bibliographic record

VenueBMJ Neurology Open · 2021
Typearticle
Languageen
FieldNeuroscience
TopicVagus Nerve Stimulation Research
Canadian institutionsnot available
FundersH2020 European Research CouncilNational Center of Neurology and PsychiatryMinisterio de Economía y CompetitividadLivaNovaRenji HospitalKing Faisal Specialist Hospital and Research CentreGeorgetown UniversityTaysMcGill University Health CentreTulane UniversityUniversity of Pennsylvania
KeywordsVagus nerve stimulationMedicineObservational studyDrug Resistant EpilepsyPittsburgh Sleep Quality IndexAdverse effectQuality of life (healthcare)EpilepsyPsychologyPsychiatryInternal medicineVagus nerveInsomnia

Abstract

fetched live from OpenAlex

INTRODUCTION: The Vagus Nerve Stimulation Therapy System (VNS Therapy) is an adjunctive neuromodulatory therapy that can be efficacious in reducing the frequency and severity of seizures in people with drug-resistant epilepsy (DRE). CORE-VNS aims to examine the long-term safety and clinical outcomes of VNS in people with DRE. METHODS AND ANALYSIS: The CORE-VNS study is an international, multicentre, prospective, observational, all-comers, post-market registry. People with DRE receiving VNS Therapy for the first time as well as people being reimplanted with VNS Therapy are eligible. Participants have a baseline visit (prior to device implant). They will be followed for a minimum of 36 months and a maximum of 60 months after implant. Analysis endpoints include seizure frequency (average number of events per month), seizure severity (individual-rated categorical outcome including very mild, mild, moderate, severe or very severe) as well as non-seizure outcomes such as adverse events, use of antiseizure medications, use of other non-pharmacological therapies, quality of life, validated measures of quality of sleep (Pittsburgh Sleep Quality Index or Children's Sleep Habit Questionnaire) and healthcare resource utilisation. While the CORE-VNS registry was not expressly designed to test hypotheses, subgroup analyses and exploratory analysis that require hypothesis testing will be conducted across propensity score matched treatment groups, where possible based on sampling. ETHICS AND DISSEMINATION: The CORE-VNS registry has already enrolled 823 participants from 61 centres across 15 countries. Once complete, CORE-VNS will represent one of the largest real-world clinical data sets to allow a more comprehensive understanding of the management of DRE with adjunctive VNS. Manuscripts derived from this database will shed important new light on the characteristics of people receiving VNS Therapy; the practical use of VNS across different countries, and factors influencing long-term response. TRAIL REGISTRATION NUMBER: NCT03529045.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.102
metaresearch head score (Gemma)0.098
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.102
Threshold uncertainty score0.537

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1020.098
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0030.004
Science and technology studies0.0020.002
Scholarly communication0.0030.004
Open science0.0030.006
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.110
GPT teacher head0.377
Teacher spread0.267 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueBMJ Neurology OpenSame topicVagus Nerve Stimulation ResearchFrench-language works237,207